Plantar Fasciitis: Drugs That Cause or Treat It

What Is Plantar Fasciitis and Why Do Drugs Matter?

Plantar fasciitis is a degenerative overuse condition of the thick band of connective tissue running from the calcaneus to the metatarsal heads. It accounts for roughly 1 million physician visits per year in the United States alone [1]. The condition is not purely mechanical. Systemic inflammation, medication side effects, and metabolic factors all shape who develops it and how quickly it resolves.

Pharmacotherapy enters the picture at two points. First, drugs treat plantar fasciitis directly by reducing pain, suppressing inflammation, or promoting tissue repair. Second, certain prescription medications can weaken tendon and fascial tissue, raising the risk of developing plantar fasciitis or delaying recovery in someone who already has it. The American Academy of Orthopaedic Surgeons (AAOS) clinical practice guideline on plantar fasciitis identifies both drug-based and non-drug treatments as components of a stepped approach, recommending that clinicians exhaust conservative options for at least six months before considering surgical release [2]. Understanding which drugs fall on which side of the equation matters for anyone managing persistent heel pain.

First-Line Drug Treatments: NSAIDs

Oral nonsteroidal anti-inflammatory drugs remain the most prescribed pharmacologic intervention. They work. A 2010 Cochrane review evaluating conservative interventions for plantar heel pain found that short-term NSAID use (2 to 4 weeks) produced statistically significant pain reduction compared to placebo, though effect sizes were modest [3].

Ibuprofen (400 to 800 mg three times daily) and naproxen (500 mg twice daily) are the most commonly used agents. Topical diclofenac gel applied over the heel has also shown efficacy in small trials, with the advantage of lower systemic exposure [4]. The key limitation: NSAIDs address pain but do not reverse the underlying fascial degeneration. They are a bridge, not a fix. The American College of Foot and Ankle Surgeons recommends limiting oral NSAID courses to 2 to 3 weeks to reduce gastrointestinal and cardiovascular risks [5].

Dr. Benedict DiGiovanni, an orthopedic foot and ankle specialist at the University of Rochester, has noted: "NSAIDs can take the edge off, but the patients who do best are the ones who pair medication with a structured stretching protocol. The drug alone rarely resolves the condition."

Acetaminophen serves as an alternative for patients who cannot tolerate NSAIDs, though it lacks anti-inflammatory properties and evidence supporting its use in plantar fasciitis specifically is limited.

Corticosteroid Injections: Fast Relief, Real Risks

Corticosteroid injections deliver potent local anti-inflammatory effect directly to the plantar fascia origin. A randomized controlled trial by McMillan et al. (2012) demonstrated that a single ultrasound-guided dexamethasone injection reduced plantar fascia thickness by 13% and VAS pain scores by 44% at 4 weeks compared to placebo [6]. The relief is real but temporary.

Pain tends to return between weeks 8 and 12 post-injection [7]. The bigger concern is structural. A systematic review by Acevedo and Beskin found that the incidence of plantar fascia rupture after corticosteroid injection was approximately 2.4%, with rupture risk increasing with repeated injections [8]. Patients with higher BMI face elevated rupture risk.

Ultrasound guidance has improved accuracy and reduced complications. A 2015 study in the Journal of Foot and Ankle Research showed that ultrasound-guided injections were 95% accurate in needle placement versus 70% for landmark-guided (palpation-based) injections [9]. Most guidelines now recommend limiting patients to no more than 3 injections per year, spaced at least 4 weeks apart.

Methylprednisolone acetate (40 mg) and triamcinolone acetonide (40 mg) are the most frequently injected agents. Dexamethasone sodium phosphate, a soluble corticosteroid, produces less fat pad atrophy but may have shorter duration of action.

Platelet-Rich Plasma: The Emerging Alternative

PRP injections concentrate autologous growth factors and deliver them to the degenerated fascia. The evidence has matured considerably. A randomized trial by Jain et al. (2015) comparing PRP to corticosteroid injection in 60 patients found that while corticosteroid produced faster initial pain relief at 3 months, PRP was superior at 12 months with a mean VAS reduction of 78% versus 56% [10].

A 2019 meta-analysis published in JAMA Network Open pooling 10 RCTs (N=524) concluded that PRP produced greater improvement in pain and function at 6 and 12 months versus corticosteroid, with no reported cases of fascial rupture [11]. The trade-off is upfront cost. PRP is rarely covered by insurance and typically runs $500 to $1,500 per injection. There is no FDA-approved PRP device specifically indicated for plantar fasciitis, though the procedure is widely performed under practice-of-medicine provisions.

Drugs That Cause or Worsen Plantar Fasciitis

Not all drug interactions with the plantar fascia are therapeutic. Several medication classes damage tendon and fascial tissue through distinct mechanisms.

Fluoroquinolone Antibiotics

Ciprofloxacin, levofloxacin, and moxifloxacin carry an FDA black-box warning for tendinitis and tendon rupture [12]. The mechanism involves direct toxicity to tenocytes through matrix metalloproteinase upregulation and oxidative stress. While Achilles tendon rupture gets the most attention, fluoroquinolones affect all tendons and fascial structures. A population-based study by Stephenson et al. (2013) found that fluoroquinolone exposure increased the risk of tendon disorders by 1.7-fold (95% CI: 1.4 to 2.0) [13]. The risk persists for up to 6 months after the last dose.

The FDA's 2016 safety communication stated: "The risk of fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in those taking corticosteroid drugs, and in kidney, heart, or lung transplant recipients" [12]. Patients already managing plantar fasciitis should request alternative antibiotics when possible.

Aromatase Inhibitors

Anastrozole, letrozole, and exemestane are prescribed for hormone receptor-positive breast cancer. Musculoskeletal symptoms affect 25 to 50% of patients, with plantar fasciitis and other tendinopathies among the reported complaints [14]. The mechanism relates to estrogen depletion. Estrogen receptors exist in tendon and fascial tissue, and their suppression impairs collagen synthesis and repair. A 2008 study in the Journal of Clinical Oncology (N=5,187) reported that arthralgia and tendon pain were the most common reason for early discontinuation of aromatase inhibitor therapy [15].

Statins

HMG-CoA reductase inhibitors (atorvastatin, rosuvastatin, simvastatin) cause myopathy in 5 to 10% of users. Tendinopathy is a less recognized but documented adverse effect. A French pharmacovigilance study identified 96 cases of statin-associated tendon complications, including 4 cases involving the plantar fascia [16]. The risk appears dose-dependent and is higher with concurrent fluoroquinolone use.

Isotretinoin

This vitamin A derivative used for severe acne has been associated with musculoskeletal complaints in up to 15% of patients [17]. Case reports describe plantar fasciitis onset during isotretinoin therapy, with symptoms resolving after drug discontinuation. The proposed mechanism involves altered extracellular matrix remodeling in fascial tissue.

Emerging and Investigational Drug Therapies

Several pharmacologic approaches are under active investigation for plantar fasciitis that has not responded to standard treatment.

Botulinum Toxin Type A

Botox injections into the plantar fascia have shown promise. A double-blind RCT by Elizondo-Rodriguez et al. (2013) randomized 36 patients to botulinum toxin A (250 units) or dexamethasone injection. At 6 months, the botulinum toxin group demonstrated a 60% mean reduction in VAS pain scores versus 41% for dexamethasone, with no reported adverse events [18]. The proposed mechanism is not merely muscle relaxation. Botulinum toxin appears to have direct analgesic properties through inhibition of substance P and calcitonin gene-related peptide release.

Topical Nitroglycerin

Glyceryl trinitrate (GTN) patches applied over the plantar fascia aim to increase local nitric oxide, which promotes collagen synthesis. A randomized trial by Paoloni et al. (2009) found that GTN patches combined with a standard stretching program produced significantly greater pain reduction at 6 months than stretching alone [19]. The patches are inexpensive and available by prescription, though headache affects 20 to 30% of users.

Prolotherapy (Dextrose Injection)

Hypertonic dextrose (12.5 to 25%) injected at the plantar fascia origin acts as a proliferant, theoretically stimulating a controlled inflammatory response that promotes tissue repair. A 2017 randomized trial (N=80) showed that prolotherapy produced pain relief equivalent to PRP at 12 months, at a fraction of the cost [20]. Evidence remains limited to small studies, and no major orthopedic guideline currently endorses prolotherapy for plantar fasciitis.

Building a Drug Therapy Ladder

The American Academy of Family Physicians (AAFP) recommends a stepped approach to plantar fasciitis pharmacotherapy [21]. Oral NSAIDs for 2 to 3 weeks form the first rung. If pain persists beyond 6 to 8 weeks despite NSAIDs and conservative measures (stretching, orthotic insoles, night splints), corticosteroid injection is appropriate. For patients who relapse after corticosteroid or who prefer to avoid rupture risk, PRP represents a durable second-line injectable.

Dr. Karl Landorf, a podiatric researcher at La Trobe University, has summarized the evidence hierarchy: "We have good short-term data for corticosteroid injection and increasingly convincing longer-term data for PRP. The challenge is matching the right intervention to the right patient at the right time point in their disease course."

Patients taking fluoroquinolones, aromatase inhibitors, or statins who develop new heel pain should have a medication review as part of their initial workup. The plantar fasciitis may be iatrogenic, and drug modification may accelerate recovery more than any injection. For the 5 to 10% of patients whose symptoms persist beyond 12 months of conservative and pharmacologic management, referral for surgical plantar fasciotomy or minimally invasive procedures becomes reasonable [2].

The most current data on PRP shows a number needed to treat (NNT) of 4 for clinically meaningful pain reduction at 12 months when compared to corticosteroid, meaning one in every four patients treated with PRP instead of steroid will experience a meaningful benefit attributable to the switch [11].